Passage Bio Inc
NASDAQ:PASG
| Market Cap (Intraday) | 47.82M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $0.71 |
| 50-Day MA | $0.83 |
| 200-Day MA | $1.05 |
Passage Bio Inc Stock, NASDAQ:PASG
One Commerce Square, 2005 Market Street, Philadelphia, Pennsylvania 19103
United States of America
Phone: +1.267.866.0311
Number of Employees: 58
Description
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.